vs
新闻集团（NWSA）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是新闻集团的2.0倍（$4.7B vs $2.4B），梯瓦制药净利率更高（10.2% vs 8.2%，领先2.0%），梯瓦制药同比增速更快（11.4% vs 5.5%），梯瓦制药自由现金流更多（$1.0B vs $132.0M），过去两年梯瓦制药的营收复合增速更高（11.1% vs -1.3%）
新闻集团是全球知名的媒体集团，旗下拥有报纸、出版、数字媒体等多项媒体业务，在全球传媒领域拥有广泛影响力，专注于为受众提供及时多元的时事资讯与内容服务。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
NWSA vs TEVA — 直观对比
营收规模更大
TEVA
是对方的2.0倍
$2.4B
营收增速更快
TEVA
高出5.9%
5.5%
净利率更高
TEVA
高出2.0%
8.2%
自由现金流更多
TEVA
多$884.0M
$132.0M
两年增速更快
TEVA
近两年复合增速
-1.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.4B | $4.7B |
| 净利润 | $193.0M | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | — | 6.4% |
| 净利率 | 8.2% | 10.2% |
| 营收同比 | 5.5% | 11.4% |
| 净利润同比 | -10.2% | 321.7% |
| 每股收益（稀释后） | $0.34 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NWSATEVA
| Q4 25 | $2.4B | $4.7B | ||
| Q3 25 | $2.1B | $4.5B | ||
| Q2 25 | $1.6B | $4.2B | ||
| Q1 25 | $2.0B | $3.9B | ||
| Q4 24 | $2.2B | $4.2B | ||
| Q3 24 | $2.6B | $4.3B | ||
| Q2 24 | $2.6B | $4.2B | ||
| Q1 24 | $2.4B | $3.8B |
净利润NWSATEVA
| Q4 25 | $193.0M | $481.0M | ||
| Q3 25 | $112.0M | $433.0M | ||
| Q2 25 | $743.0M | $282.0M | ||
| Q1 25 | $103.0M | $214.0M | ||
| Q4 24 | $215.0M | $-217.0M | ||
| Q3 24 | $119.0M | $-437.0M | ||
| Q2 24 | $50.0M | $-846.0M | ||
| Q1 24 | $30.0M | $-139.0M |
毛利率NWSATEVA
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
营业利润率NWSATEVA
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 19.7% | ||
| Q2 25 | 8.5% | 10.9% | ||
| Q1 25 | 7.5% | 13.3% | ||
| Q4 24 | 19.2% | -0.7% | ||
| Q3 24 | 7.9% | -1.2% | ||
| Q2 24 | 4.3% | -0.1% | ||
| Q1 24 | 2.6% | -5.7% |
净利率NWSATEVA
| Q4 25 | 8.2% | 10.2% | ||
| Q3 25 | 5.2% | 9.7% | ||
| Q2 25 | 45.6% | 6.8% | ||
| Q1 25 | 5.1% | 5.5% | ||
| Q4 24 | 9.6% | -5.1% | ||
| Q3 24 | 4.6% | -10.1% | ||
| Q2 24 | 1.9% | -20.3% | ||
| Q1 24 | 1.2% | -3.6% |
每股收益（稀释后）NWSATEVA
| Q4 25 | $0.34 | $0.42 | ||
| Q3 25 | $0.20 | $0.37 | ||
| Q2 25 | $1.30 | $0.24 | ||
| Q1 25 | $0.18 | $0.18 | ||
| Q4 24 | $0.38 | $-0.19 | ||
| Q3 24 | $0.21 | $-0.39 | ||
| Q2 24 | $0.09 | $-0.75 | ||
| Q1 24 | $0.05 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.1B | $3.6B |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $8.8B | $7.9B |
| 总资产 | $15.5B | $40.7B |
| 负债/权益比越低杠杆越低 | 0.22× | — |
8季度趋势，按日历期对齐
现金及短期投资NWSATEVA
| Q4 25 | $2.1B | $3.6B | ||
| Q3 25 | $2.2B | $2.2B | ||
| Q2 25 | $2.4B | $2.2B | ||
| Q1 25 | $2.1B | $1.7B | ||
| Q4 24 | $1.8B | $3.3B | ||
| Q3 24 | $1.8B | $3.3B | ||
| Q2 24 | $2.0B | $2.3B | ||
| Q1 24 | $1.9B | $3.0B |
总债务NWSATEVA
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.9B | — | ||
| Q2 24 | $2.9B | — | ||
| Q1 24 | $2.9B | — |
股东权益NWSATEVA
| Q4 25 | $8.8B | $7.9B | ||
| Q3 25 | $8.7B | $7.3B | ||
| Q2 25 | $8.8B | $6.8B | ||
| Q1 25 | $8.2B | $6.3B | ||
| Q4 24 | $8.1B | $5.4B | ||
| Q3 24 | $8.3B | $6.1B | ||
| Q2 24 | $8.1B | $6.4B | ||
| Q1 24 | $8.1B | $7.3B |
总资产NWSATEVA
| Q4 25 | $15.5B | $40.7B | ||
| Q3 25 | $15.3B | $39.9B | ||
| Q2 25 | $15.5B | $40.1B | ||
| Q1 25 | $16.6B | $38.4B | ||
| Q4 24 | $16.2B | $39.3B | ||
| Q3 24 | $16.9B | $41.8B | ||
| Q2 24 | $16.7B | $41.3B | ||
| Q1 24 | $16.5B | $42.8B |
负债/权益比NWSATEVA
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.22× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.24× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $231.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $132.0M | $1.0B |
| 自由现金流率自由现金流/营收 | 5.6% | 21.6% |
| 资本支出强度资本支出/营收 | 4.2% | 3.0% |
| 现金转化率经营现金流/净利润 | 1.20× | 2.41× |
| 过去12个月自由现金流最近4个季度 | $586.0M | $1.1B |
8季度趋势，按日历期对齐
经营现金流NWSATEVA
| Q4 25 | $231.0M | $1.2B | ||
| Q3 25 | $85.0M | $369.0M | ||
| Q2 25 | $189.0M | $227.0M | ||
| Q1 25 | $511.0M | $-105.0M | ||
| Q4 24 | $252.0M | $575.0M | ||
| Q3 24 | $64.0M | $693.0M | ||
| Q2 24 | $254.0M | $103.0M | ||
| Q1 24 | $539.0M | $-124.0M |
自由现金流NWSATEVA
| Q4 25 | $132.0M | $1.0B | ||
| Q3 25 | $4.0M | $233.0M | ||
| Q2 25 | $32.0M | $131.0M | ||
| Q1 25 | $418.0M | $-232.0M | ||
| Q4 24 | $190.0M | $446.0M | ||
| Q3 24 | $-31.0M | $545.0M | ||
| Q2 24 | $111.0M | $6.0M | ||
| Q1 24 | $422.0M | $-248.0M |
自由现金流率NWSATEVA
| Q4 25 | 5.6% | 21.6% | ||
| Q3 25 | 0.2% | 5.2% | ||
| Q2 25 | 2.0% | 3.1% | ||
| Q1 25 | 20.8% | -6.0% | ||
| Q4 24 | 8.5% | 10.5% | ||
| Q3 24 | -1.2% | 12.6% | ||
| Q2 24 | 4.3% | 0.1% | ||
| Q1 24 | 17.4% | -6.5% |
资本支出强度NWSATEVA
| Q4 25 | 4.2% | 3.0% | ||
| Q3 25 | 3.8% | 3.0% | ||
| Q2 25 | 9.6% | 2.3% | ||
| Q1 25 | 4.6% | 3.3% | ||
| Q4 24 | 2.8% | 3.1% | ||
| Q3 24 | 3.7% | 3.4% | ||
| Q2 24 | 5.5% | 2.3% | ||
| Q1 24 | 4.8% | 3.2% |
现金转化率NWSATEVA
| Q4 25 | 1.20× | 2.41× | ||
| Q3 25 | 0.76× | 0.85× | ||
| Q2 25 | 0.25× | 0.80× | ||
| Q1 25 | 4.96× | -0.49× | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 5.08× | — | ||
| Q1 24 | 17.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NWSA
| Book Publishing Segment | $633.0M | 27% |
| Consumer | $607.0M | 26% |
| News And Information Services Segment | $570.0M | 24% |
| Real Estate | $401.0M | 17% |
| Other Product Or Service | $173.0M | 7% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
